Applying to Medical School in the COVID-19 Era

Arjun D. Bhatt, BS; and Deepak L. Bhatt, MD, MPH

The already daunting process of applying to medical school has become even more stressful for premed students in this time of social distancing, tele-based meetings, and the general fear of COVID-19.1 For many aspiring medical-school applicants, there is an increased sense of stress, as carefully charted paths to medical school become so utterly disrupted. Many of the traditional aspects of applying to medical school—Medical College Admissions Testing (MCAT); volunteering or working in hospitals; studying for long hours; and, if one is lucky enough, interviewing with medical schools—have all been greatly affected by this global pandemic. Colleges and universities around the country, for fear of becoming hot spots for COVID-19, have mandated students to vacate campuses and resume classes virtually. This poses several challenges to the potential medical-school applicant (Table). Indeed, this pandemic may stimulate changes to medical education that were long overdue.2,3

One of the biggest components of applying to medical school is taking the MCAT. However, the COVID-19 pandemic forced testing to be canceled for nearly 2 months and even caused the American Association of Medical Colleges (AAMC) to administer a shortened version of the MCAT. The premed students scheduled for those canceled dates were tasked with rescheduling the exam, and this delay in testing may have caused significant tension, as many have meticulously crafted plans for when to take the test. The MCAT could potentially be administered online to temper these disruptions and to provide constant service, moving forward. This would require the test takers to be monitored through a Webcam-based system in conjunction with possibly downloading testing software to ensure that no outside applications or resources are used. Although some may have challenges operating the technology, many may find this to be an easier alternative to driving to a test center, especially for those who live in rural areas where the closest testing center may be far away.

Along with MCAT testing, the average premed student typically volunteers or works in a hospital or laboratory in some capacity. Unfortunately, the social distancing and stay-at-home orders that had been placed caused many premed students to lose access to these opportunities. For example, most nursing homes have suspended all volunteer activities and visitation privileges in hopes of protecting their residents. Common premed jobs, such as scribe positions and medical assistants, were suspended for months, as physicians have many times transitioned to working from home remotely. Similarly, many basic science laboratories were closed for a period of months, and premed research assistants were not allowed to perform any on-site activities. Nevertheless, new online opportunities have arisen. In many states, for instance, the virtual job of contact tracing to aid in the fight against COVID-19 presented a novel opportunity for premedical students. This unfortunate pandemic has provided prospective medical school students the chance to help in a situation that is unprecedented in our generation. It is hoped that these challenges induced by the COVID-19 pandemic might also allow for applicants to experience personal growth; not everything will go according to plan, and learning how to adapt and overcome challenges is crucial, especially in the practice of medicine. Indeed, this generation of
applicants will be well versed in dealing with the unexpected.

Every hopeful premed student understands the importance of the medical school interview process and, as such, spends the necessary amount of time preparing. How do medical schools adapt now that in-person interviews clash with social distancing guidelines set by the Centers for Disease Control and Prevention (CDC)? Like many others who are now turning to the virtual world, medical school interviews may be conducted online through systems such as Zoom or Google Hangouts. This new online direction may have disadvantages, such as inability to actually read people and have more natural conversations. On the other hand, many students may find the virtual interview to provide a more comfortable setting from which to be interviewed; applicants may be more secure and less anxious while in their own homes. Overall, prospective students may find the virtual interviews to be a less intimidating process while still being engaging. As this pandemic has demonstrated, telemedicine is effective and may very well continue to play a vital role in health care for many years.² By having applicants become familiar with the tele-based technology, medical schools will be creating physicians of the future.

Many students applying to medical school face an enormous barrier: cost.⁴⁻⁷ Indeed, the perceived and actual costs of applying to medical school dissuade many potential applicants who often fear applying to institutions far from home because of travel expenses. This worry is compounded, given the current economic climate. Families and communities across the country are facing financial uncertainty, as we are all still in doubt about the future. Minority communities, rural areas, and lower-income families have been hit especially hard economically during this time, as well as facing a disproportionate amount of morbidity and mortality caused by COVID-19. Students who would have otherwise been unable to apply to certain schools may now be able to overcome such hurdles because of the absence of travel costs. Once again, the pandemic offers an opportunity to reassess the status quo in a way that may prove beneficial, particularly to socioeconomically disadvantaged groups.² This could turn out to be the biggest silver lining of the pandemic.

There is much fear that there will be a second wave of COVID-19, as there was a resurgence with the influenza pandemic of 1918. Fears have been shared by the CDC director, as he has remarked that the country’s health workers may be overwhelmed should there be a combined COVID-19 and influenza season. Unlike other disasters, no one currently alive has any experience with a pandemic. The wisdom of elders of the 1918 pandemic is lost other than in the written word. Thus, there is enormous collective social anxiety, and medical students—an anxious bunch under the best of circumstances—are under tremendous stress: a fact those involved in the selection process must acknowledge and try to mitigate. Nevertheless, medical students are also some of the most resilient young people, and this struggle with COVID-19 will only make them dream bigger, work harder, and achieve more. Ultimately, this pandemic may bring forth medical school applicants ideally primed to tackle the uncertainties of modern-day medical practice.

CONCLUSION

Despite the challenges noted, witnessing selfless health care workers on the frontlines of the COVID-19 pandemic has
inspired premedical students and likely strengthened their resolve to apply to medical schools. This moment of heightened altruism thus offers the opportunity for medical schools to streamline the admissions process and for medical school applicants to rise to the challenge.8-10

ACKNOWLEDGMENT

The authors thank Dr. Lisa S. Rosenbaum, Brigham and Women’s Hospital, Boston, Massachusetts, for her very helpful reviews of this article.

Potential Competing Interests: Dr. Bhatt serves on Advisory Boards for Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, and Regado Biosciences. He serves on the Board of Directors for Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft, and as Chair for American Heart Association Quality Oversight Committee. In addition, he has served on Data Monitoring Committees for Bain Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daichi Sankyo), Population Health Research Institute. He has received honoraria from American College of Cardiology (Senior Associate Editor; Clinical Trials and News, ACCcorg Vice-Chair; ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medintelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Stack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees). He has also served as Deputy Editor for Clinical Cardiology and as Chair of NCDR-ACTION Registry Steering Committee and VA CART Research and Publications Committee. He has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, sanofi-aventis, Synaptic, The Medicines Company and royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator for Biotronik, Boston Scientific, CSL St. Jude Medical (now Abbott), and Svelte and has served as Trustee of American College of Cardiology. Unfunded Research: FlowCo, Merck, Novo Nordisk, and Takeda. Dr. Bhatt reports no competing interests.

Correspondence: Address to Deepak L. Bhatt, MD, MPH, Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115 (DLBhattMD@post.Harvard.edu; Twitter: @DLBhattMD).

ORCID

Arjun D. Bhatt: https://orcid.org/0000-0003-3799-6975; Deepak L. Bhatt: https://orcid.org/0000-0002-1278-6245

REFERENCES